title: Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients.
abstract: BACKGROUND
  Cabergoline fails to normalize hyperprolactinemia in a considerable proportion of prolactinomas, especially macroadenomas.
  
  
  OBJECTIVE
  We examined the effect of individualized high-dose cabergoline treatment on hyperprolactinemia in prolactinomas.
  
  
  METHODS
  The study included 122 women and 28 men (93 microadenomas and 57 macroadenomas). Forty-seven had undergone transsphenoidal surgery. According to the preceding medical treatment, the participants were separated into untreated (group U; n = 60), intolerant (group I; n = 64), and resistant (group R; n = 26) groups.
  
  
  METHODS
  We promptly increased cabergoline dose on the basis of individual prolactin levels. Length of treatment was 1 yr.
  
  
  RESULTS
  Cabergoline normalized hyperprolactinemia in all patients except one. The proportion of prolactin normalization in both groups U and I was 83% at 3 months and 95% at 6 months. By contrast, that in group R was 35% at 3 months and 58% at 6 months. Mean cabergoline dose in milligrams per week at the time of prolactin normalization was 2.0 +/- 0.3 in group U, 0.9 +/- 0.1 in group I, and 5.2 +/- 0.6 in group R. Prolactin normalization rate at the 3 mg/wk dose was 84% overall but only 35% in group R. Serum progesterone or testosterone levels, diminished in 122 women or 16 men, respectively, were recovered in all except one resistant and four postmenopausal or panhypopituitary patients.
  
  
  CONCLUSIONS
  Individualized high-dose cabergoline treatment can normalize hyperprolactinemia and hypogonadism in nearly all prolactinomas irrespective of tumor size or preceding treatments. Hyperprolactinemia could be controlled in poor responders within 1 yr with doses higher than 3 mg/wk.
authors.affiliation: Department of Medicine II, Institute of Clinical Endocrinology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. miki-masa@abox3.so-net.ne.jp
authors.forename: Masami
authors.initials: M
authors.lastname: Ono
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Miki
authors.forename: Takakazu
authors.initials: T
authors.lastname: Kawamata
authors.forename: Rena
authors.initials: R
authors.lastname: Makino
authors.forename: Kosaku
authors.initials: K
authors.lastname: Amano
authors.forename: Toshiro
authors.initials: T
authors.lastname: Seki
authors.forename: Osami
authors.initials: O
authors.lastname: Kubo
authors.forename: Tomokatsu
authors.initials: T
authors.lastname: Hori
authors.forename: Kazue
authors.initials: K
authors.lastname: Takano
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077465:Cabergoline; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004351:Drug Resistance; D004873:Ergolines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D004873:Ergolines; D011388:Prolactin; D000077465:Cabergoline